Unwanted effects and interaction of intrajejunal levodopa/carbidopa administration

Bibliography

• Rascol O, Lozano A, Stern M, Poewe W. Milestones in parkinson's disease therapeutics. Mov Disord 2011;26:1072-82
   PubMed Web of Science ®Google Scholar
• Markham CH, Diamond SG. Long term follow-up of early dopa treatment in parkinson's disease. Ann Neurol 1986;19:365-72
   PubMed Web of Science ®Google Scholar
• Marsden C. Problems with long-term levodopa therapy for parkinson's disease. Clin Neuropharmacol 1994;17:32-44
   PubMedGoogle Scholar
• Nutt JG. Pharmacokinetics and pharmacodynamics of levodopa. Mov Disord 2008;23(Suppl 3):S580-4
   PubMed Web of Science ®Google Scholar
• Ossig C, Reichmann H. Treatment of parkinson's disease in the advanced stage. J Neural Transm 2013;120:523-9
   PubMed Web of Science ®Google Scholar
• De la Fuente-Fernandez R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001;49:298-303
   PubMed Web of Science ®Google Scholar
• Jost WH. Gastrointestinal motility problems in patients with parkinson's disease: effects of antiparkinsonian treatment and guidelines for management. Drugs Aging 1997;10:249-58
   PubMed Web of Science ®Google Scholar
• Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-87
   PubMed Web of Science ®Google Scholar
• Kurlan R, Rubin AJ, Miller C, et al. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986;20:262-5
   PubMed Web of Science ®Google Scholar
• Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-10
   PubMed Web of Science ®Google Scholar
• Antonini A, Isaias IU, Rodolfi G, et al. A 5-year prospective assessment of advanced parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. J Neurol 2011;258:579-85
   PubMed Web of Science ®Google Scholar
• Volkmann J, Albanese A, Antonini A, et al. Selecting deep brain stimulation or infusion therapies in advanced parkinson's disease: an evidence-based review. J Neurol 2013;260:2701-14
   PubMed Web of Science ®Google Scholar
• Deuschl G, Schade-Brittinger C, Krack P, et al. A randomised trial of deep-brain stimulation for parkinson's disease. N Engl J Med 2006;355:896-908
   PubMed Web of Science ®Google Scholar
• Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for parkinson's disease with early motor complications. N Engl J Med 2013;368:610-22
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim S-Y, et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of parkinson's disease. Mov Disord 2011;26(Suppl 3):S2-41
   PubMed Web of Science ®Google Scholar
• Merola A, Zibetti M, Angrisano S, et al. Comparison of subthalamic nucleus deep brain stimulation and duodopa in the treatment of advanced parkinson's disease. Mov Disord 2011;26:664-70
   PubMed Web of Science ®Google Scholar
• Kempster PA, O'Sullivan SS, Holton JL, et al. Relationships between age and late progression of parkinson's disease: a clinic-pathological study. Brain 2010;133:1755-62
   PubMed Web of Science ®Google Scholar
• Nyholm D, Klangemo K, Johansson A. Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced parkinson's disease. Eur J Neurol 2012;19:1079-85
   PubMed Web of Science ®Google Scholar
• Pedersen SW, Clausen J, Gregerslund MM. Practical guidance on how to handle levodopa/carbidopa intestinal gel therapy of advanced PD in a movement disorder clinic. Open Neurol J 2012;6:37-50
   PubMedGoogle Scholar
• Duodopa. Product Monograph 2011, Abbott Labara tories, Saint-Laurent, Quebec, 1-44
   Google Scholar
• Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced parkinson disease. Neurology 2005;64:216-23
   PubMed Web of Science ®Google Scholar
• Nyholm D, Odin P, Johansson A, et al. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced parkinson's disease patients. AAPS J 2013;15:316-23
   PubMed Web of Science ®Google Scholar
• Nyholm D Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156-63
   PubMed Web of Science ®Google Scholar
• Eggert K, Schrader C, Hahn M, et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31:151-66
   PubMed Web of Science ®Google Scholar
• Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-74
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Vanagunas A, Odin P, et al. Levodopa–carbidopa intestinal gel in advanced parkinson's disease open-label study: interim results. Parkinsonism Relat Disord 2013;19:339-45
   PubMed Web of Science ®Google Scholar
• Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2014;13:141-9
   PubMed Web of Science ®Google Scholar
• Pålhagen SE, Dizdar N, Hauge T, et al. Interim analysis of long-term intraduodenal levodopa infusion in advanced parkinson disease. Acta Neurol Scand 2012;126:e29-33
   PubMed Web of Science ®Google Scholar
• Nyholm D, Lewander T, Johansson A, et al. Enteral levodopa/carbidopa infusion in advanced parkinson disease: long-term exposure. Clin Neuropharmacol 2008;31:63-73
   PubMed Web of Science ®Google Scholar
• Zibetti M, Merola A, Artusi CA, et al. Levodopa/carbidopa intestinal gel infusion in advanced parkinson's disease: a 7-year experience. Eur J Neurol 2013. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Syed N, Murphy J, Zimmerman T Jr, et al. Ten years' experience with enteral levodopa infusion for motor fluctuations in parkinson's disease. Mov Disord 1998;13:336-8
   PubMed Web of Science ®Google Scholar
• Nyholm D. Duodopa treatment for advanced parkinson's disease: a review of efficacy and safety. Parkinsonism Relat Disord 2012;18:916-29
   PubMed Web of Science ®Google Scholar
• Itkin M, DeLegge MH, Fang JC, et al. Multidisciplinary practical guidelines for gastrointestinal access for enteral nutrition and decompression from the society of interventional radiology and american gastroenterological association (AGA) institute, with endorsement by canadian interventional radiological association (CIRA) and cardiovascular and interventional radiological society of europe (CIRSE). Gastroenterology 2011;141:742-65
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Odin P. Levodopa-carbidopa intestinal gel for treatment of advanced parkinson's disease. Curr Med Res Opin 2011;27:907-19
   PubMed Web of Science ®Google Scholar
• Klostermann F, Jugel C, Müller T, Marzinzik F. Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm 2012;119:369-72
   PubMed Web of Science ®Google Scholar
• Klostermann F, Jugel C, Bömelburg M, et al. Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion. Mov Disord 2012;27:1704-5
   PubMed Web of Science ®Google Scholar
• Urban PP, Wellach I, Faiss S, et al. Subacute axonal neuropathy in parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord 2010;25:1748-52
   PubMed Web of Science ®Google Scholar
• Manca D, Cossu G, Murgia D, et al. Reversible encephalopathy and axonal neuropathy in parkinson's disease during duodopa therapy. Mov Disord 2009;24:2293-4
   PubMed Web of Science ®Google Scholar
• Santos-García D, de la Fuente-Fernández R, Valldeoriola F, et al. Polyneuropathy while on duodenal levodopa infusion in parkinson's disease patients: we must be alert. J Neurol 2012;259:1668-72
   PubMed Web of Science ®Google Scholar
• Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22:1145-9
   PubMed Web of Science ®Google Scholar
• Onofrj M, Bonanni L, Cossu G, et al. Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment. Parkinsonism Relat Disord 2009;15(Suppl 3):S233-6
   PubMedGoogle Scholar
• Hin H, Clarke R, Sherliker P, et al. Clinical relevance of low serum vitamin B12 concentrations in older people: the banbury B12 study. Age Ageing 2006;35:416-22
   PubMed Web of Science ®Google Scholar
• Triantafyllou NI, Nikolaou C, Boufidou F, et al. Folate and vitamin B12 levels in levodopa-treated parkinson's disease patients: their relationship to clinical manifestations, mood and cognition. Parkinsonism Relat Disorders 2008;14:321-5
   PubMed Web of Science ®Google Scholar
• Toth C, Breithaupt K, Ge S, et al. Levodopa, methylmalonicacid and neuropathy in idiopathic parkinson's disease. Ann Neurol 2010;67:28-36
   Google Scholar
• Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003;60:59-64
   PubMed Web of Science ®Google Scholar
• Miller JW, Selhub J, Nadeau MR, et al. Effect of L-dopa on plasma homocysteine in PD patients on relationship to B-vitamin status. Neurology 2003;60:1125-9
   PubMed Web of Science ®Google Scholar
• Yasui K, Kowa H, Nakaso K, et al. Plasma homocysteine and MTHFR C677T genotype in levodopa treated patients with PD. Neurology 2000;55:437-40
   PubMed Web of Science ®Google Scholar
• Lamberti P, Zoccolela S, Iliceto G, et al. Effects of levodopa and COMT inhibitors on plasma homocysteine parkinson's disease patients. Mov Disord 2005;20:69-72
   PubMed Web of Science ®Google Scholar
• Zoccolela S, Lamberti P, Armenise E, et al. Plasma homocysteine levels in parkinson's disease: role of antiparkinsonian medications. Parkinsonism Relat Disord 2005;11:131-3
   PubMed Web of Science ®Google Scholar
• O' Suilleabhain PE, Bottigleri T, Dewey RB Jr, et al. Modest increase in plasma homocysteine follows levodopa initiation in parkinson's disease. Mov Disord 2004;19:1403-8
   PubMed Web of Science ®Google Scholar
• Müller T, Jugel C, Ehret R, et al. Elevation of total homocysteine levels in patients with parkinson's disease treated with duodenal levodopa/carbidopa gel. J Neural Transm 2011;118:1329-33
   PubMed Web of Science ®Google Scholar
• Müller T, van Laar T, Cornblath DR, et al. Peripheral neuropathy in parkinson's disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord 2013;19:501-7
   PubMed Web of Science ®Google Scholar
• Müller T, Renger K, Kuhn W. Levodopa-associated increase of homocysteine levels and sural axonal degeneration. Arch Neurol 2004;61:657-60
   PubMed Web of Science ®Google Scholar
• Teodoro T, Pires D, Rosa MM, et al. Has “levodopa-induced neuropathy” been reported in parkinson's disease trials? Mov Disord 2011;26:1966
   PubMed Web of Science ®Google Scholar
• Allain P, Le Bouil A, Cordillet E, et al. Sulphate and cysteine levels in the plasma of patients with parkinson's disease. Neurotoxicology 1995;16:527-9
   PubMed Web of Science ®Google Scholar
• Kuhn W, Roebroek R, Blom H, et al. Hyperhomocysteinaemia in parkinson's disease. J Neurol 1998;245:811-12
   PubMed Web of Science ®Google Scholar
• Postuma RB, Espay AJ, Zadikoff C, et al. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 2006;66:1941-3
   PubMed Web of Science ®Google Scholar
• Madenci G, Bilen S, Arli B, et al. Serum iron, vitamin B12 and folic acid levels in parkinson's disease. Neurochem Res 2012;37:1436-41
   PubMed Web of Science ®Google Scholar
• Toth C, Brown MS, Furtado S, et al. Neuropathy as a potential complication of levodopa use in parkinson's disease. Mov Disord 2008;23:1850-9
   PubMed Web of Science ®Google Scholar
• Montastruc JL, Danton AC, Durrieu G, et al. French Association of Regional Pharmaco Vigilance Centres. Neuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of view. Mov Disord 2010;660-1
   PubMed Web of Science ®Google Scholar
• Ceravolo R, Cossu G, Bandettini di Poggio M, et al. Neuropathy and levodopa in parkinson's disease: evidence from a multicenter study. Mov Disord 2013;28:1391-7
   PubMed Web of Science ®Google Scholar
• Jugel C, Ehlen F, Taskin B, et al. Neuropathy in parkinson's disease patients with intestinal levodopa infusion versus oral drugs. PLoS One 2013;8:e66639
   PubMed Web of Science ®Google Scholar
• Santos-García D, Macías M, Llaneza M, et al. Serum vitamin B12 and folate levels in parkinson's disease patients treated with duodenal levodopa infusion. Mov Disord 2011;26:558-9
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Martey J. Neuropathy in parkinson disease: prevalence and determinants. Neurology 2011;77:1947-50
   PubMed Web of Science ®Google Scholar
• Merola A, Zibetti M, Rizzone MG, et al. Prospective assessment of peripheral neuropathy in duodopa-treated parkinsonian patients. Acta Neurol Scand 2014;129(1):e1-5
   PubMed Web of Science ®Google Scholar
• Zibetti M, Merola A, Ricchi V, et al. Long-term duodenal levodopa infusion in parkinson's disease: a 3-year motor and cognitive follow-up study. J Neurol 2013;26:105-14
   Google Scholar
• Green R, Kinsella L. Current concepts in the diagnosis of cobalamin defiency. Neurology 1995;45:1435-40
   PubMed Web of Science ®Google Scholar
• Santos-Garcia D, Sanjurjo LF, Macías M, et al. Long-term exposure to duodenal levodopa/carbidopa infusion therapy improves quality of life in relation especially to mobility, activities of daily living, and emotional well-being. Acta Neurol Scand 2012;125:187-91
   PubMed Web of Science ®Google Scholar
• Nyholm D, Johansson A, Aquilonius SM. Complexity of motor response to different doses of duodenal levodopa infusion in parkinson disease. Clin Neuropharmacol 2012;35:6-14
   PubMed Web of Science ®Google Scholar
• Jost W, Südmeyer M, Winkler C. Kontinuierliche intestinale L-Dopa-Gabe und B-Vitamine: was ist zu beachten? Akt Neurol 2013;40:343-5
   Google Scholar
• Dengler I, Leukel N, Meuser T, Jost WH. Prospektive erfassung der direkten und indirektes kosten des idiopathischen parkinson-Syndroms. Nervenarzt 2006;77:1204-9
   PubMedGoogle Scholar
• Lowin J, Bergman A, Chaudhuri KR, et al. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage parkinson's disease in the UK. J Med Econ 2011;14:584-93
   PubMedGoogle Scholar
• Abbruzzese G, Barone P, Bonuccelli U, et al. Continuous intestinal infusion of levodopa/carbidopa in advanced parkinson's disease: efficacy, safety and patient selection. Funct Neurol 2012;27:147-54
   PubMed Web of Science ®Google Scholar
• Devos D; French Duodopa Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced parkinson's disease. Mov Disord 2009;24:993-1000
   PubMed Web of Science ®Google Scholar
• Foltynie T, Magee C, James C, et al. Impact of duodopa on quality of life in advanced parkinson's disease: a UK case series. Parkinsons Dis 2013;2013:362908
   PubMedGoogle Scholar
• Puente V, De Fabregues O, Oliveras C, et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced parkinson's disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord 2010;16:218-21
   PubMed Web of Science ®Google Scholar